Investigation of TDP-43 and annexin A11 contributions to off-target tau-PET binding in frontotemporal lobar degeneration: a retrospective, observational study
The Lancet Medical Imaging & Theranostics · 2026
DOI: 10.1016/j.lanmit.2026.100013 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026. Verfasst von Rodolfo Gabriel Gatto und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Avid Radiopharmaceuticals, National Institutes of Health.
Abstract (Originalsprache)
Background
A subset of frontotemporal lobar degeneration (FTLD) cases has phosphorylated transactive response DNA-binding protein 43 (TDP-43) inclusions (FTLD-TDP). However, flortaucipir PET, which detects paired helical filament tau, shows uptake in FTLD-TDP cases. Annexin A11 (ANXA11) has also been identified in a subset of FTLD-TDP cases. Hence, in this study, we aimed to ascertain whether flortaucipir-PET uptake overlaps with phosphorylated TDP-43 or ANXA11 aggregates, or both.
Methods
Brain tissues from eight cases: one control, one with high-level Alzheimer's disease without TDP-43, one with low-level Alzheimer's disease with TDP-43, one high-level Alzheimer's disease with TDP-43, and four FTLD-TDP cases (one FTLD-type A and three FTLD-type C) were included. The superior and middle frontal gyrus, superior and middle temporal gyrus, hippocampal dentate gyrus, and basal ganglia putamen regions were analysed. Colocalisation between a flortaucipir analogue (T726) and TDP-43 and ANXA11 was assessed using ImageJ software.
Findings
Recruitment for this study was conducted between Nov 10, 2016, and March 3, 2020. Owing to the small size of the cohort, data regarding sex, race, and ethnicity were not systematically collected or analysed to ensure anonymity for the purposes of this retrospective study. Colocalisation between T726 and hyperphosphorylated tau (pS396) was observed in all three Alzheimer's disease cases. ANXA11 was present in all three FTLD-TDP type C cases, minimally in FTLD-TDP type A, and negligible in Alzheimer's disease+TDP-43 cases. Colocalisation of T726 with phosphorylated TDP-43 and ANXA11 was observed for all FTLD-TDP type C cases, more in the hippocampal dentate gyrus and superior and middle temporal gyrus regions, and less in the superior and middle frontal gyrus and basal ganglia putamen regions.
Interpretation
Flortaucipir uptake in FTLD-TDP, particularly type C, could reflect off-target binding to phosphorylated TDP-43 and ANXA11 aggregates in limbic regions rather than tau pathology alone; consequently, tau-PET signal in frontotemporal syndromes should be interpreted cautiously, as the signal could capture non-tau proteinopathies and influence diagnostic and biomarker applications. Funding National Institutes of Health.
Förderung
- Avid Radiopharmaceuticals
- National Institutes of Health
Zitieren
APA
Gatto, R. G., Uruk, G., Youssef, H., Reichard, R. R., Lowe, V. J., Whitwell, J. L., & Josephs, K. A. (2026). Investigation of TDP-43 and annexin A11 contributions to off-target tau-PET binding in frontotemporal lobar degeneration: a retrospective, observational study. The Lancet Medical Imaging & Theranostics. https://doi.org/10.1016/j.lanmit.2026.100013
Vancouver
Gatto RG, Uruk G, Youssef H, Reichard RR, Lowe VJ, Whitwell JL, et al. Investigation of TDP-43 and annexin A11 contributions to off-target tau-PET binding in frontotemporal lobar degeneration: a retrospective, observational study. The Lancet Medical Imaging & Theranostics. 2026. doi:10.1016/j.lanmit.2026.100013
BibTeX
@article{Gatto2026,
author = {Gatto, Rodolfo Gabriel and Uruk, Gokhan and Youssef, Hossam and Reichard, Robert Ross and Lowe, Val John and Whitwell, Jennifer Louise and Josephs, Keith Anthony},
title = {Investigation of TDP-43 and annexin A11 contributions to off-target tau-PET binding in frontotemporal lobar degeneration: a retrospective, observational study},
journal = {The Lancet Medical Imaging & Theranostics},
year = {2026},
doi = {10.1016/j.lanmit.2026.100013}
}
EUVIMED